Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - BioSpace
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer BioSpace
Assessing the Accuracy of Cardiovascular Disease Prediction Using Female-Specific Risk Factors in Women Aged 45 to 69 Years in the UK Biobank Study.
Cardiovascular disease (CVD) is the leading cause of mortality in women. We aimed to assess whether adding female-specific risk factors to traditional factors could improve CVD risk prediction.
A high concentration of neutrophil extracellular traps is observed in humans and mice suffering from endometriosis.
We wished to ascertain if there is an association between neutrophil extracellular traps and endometriosis (EMS). We collected the lesional tissues and normal endometrium of 30 patients suffering from endometriosis. …
Retinoids, particularly all-trans-retinoic acid (ATRA), play crucial roles in various physiological processes, including development, immune response, and reproduction, by regulating gene transcription through nuclear receptors. This review explores the biosynthetic …
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - The Malaysian Reserve
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer The Malaysian Reserve
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - Canada NewsWire
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer Canada NewsWire